Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
congrat
but if you have to get a serious board you have to act serious - ok ?
that what you did till now was not serious - it was like all pushers did and do - IMO
thomas
I was left high and dry
good joke
where are the newsflow you told herscu ?
prpm was also up 100%
what about prpm ?
OGNG up over 100% since alert
PRPM should still make some big moves in early 2013 my friend, its just a quiet time now.. would have been good if they released the last PR sooner it was about a week too late.. still hearing plenty of upside here!
FB, what are you hearing on PRPM? Really seems to have really gone pear shaped. Clearly not what new management were trying to achieve with last weeks press release.
In the end it didn't matter, stock went down anyway.
Apologies, ignore me on the other side of the world get my dates mixed up. I now realise Ann was released after market close on the 19th. Should be an interesting day.
Why didn't the stock go up on Wednesdays news? It's a real worry.
what do you think ?
the stock went from 0,0001 to 0,0004/0,0005
a rogue who thinks about xxx -
IMO
FB, really small volumes on the PRPM, what are you hearing?
Thanks, I certainly hope so.
yep i think we will hopefully we hit .0008++ this week
Do you think we may get some news from PRPM this week?
from what i heard there should b plenty of huge news coming i think 0004' and .0005 wont last long. just my opinion tho
I would certainly like to see more but happy to take 0.001 if it can get there quickly, really struggling to get above 0.0005
yea thats what im looking for at least
Where do you think it can get to, 0.001?
imo a good thing lol still on high alert
Yes, is that a good thing or a bad thing?
still holding prpm?
PRPM up 100%+ since alert last week going much higher
Look forward to it, I was disappointed it closed at 0.0003 Thursday.
PRPM should see some teaser news soon followed by more substantial news in the coming weeks.. double zeros coming soon imo
FB, so what am I looking for on PRPM? News release soon?
imo PRPM going higher going than .0004
personally im holding to see double zeros atleast
As they say you snooze you loose. Up 100% yesterday 52 week high. Should I still be buying?
FB, give me a chance laugh out loud.
hope you got some PRPM!! if not don't miss out on the .0004's.. Going much higher in the coming weeks imo
who knows lol but its time to move up has come hope you got some .0002s i think this will see double zeros soon
was at 10ct 4 years ago - why this crashdown ?
PRPM buy and hold is the call here at .0002
hearing plenty of good things coming could be a ten bagger ++ easily
Thanks Tom, I appreciate your thoughts.
my guess ->
good things take time and thats what we will see at bldwthe last news was great, this guy isn´t any number he is a good known and connect investor
i know we all want to see +10 000% in some days but that is one time in your life maybe
i for myself will be very lucky if we see here a straight growing company and some news which will help the stockprice
i was also frustreted in the beginning but now you see stockprice 4,5-6ct since some days - this week is silent because of "thanksgiving week"
i don´t tell you to go IN or go OUT of stock but i for myself will look forward to a growing company
thomas
I'm interested in your thoughts on bldw if you care to share please.
BFGC should see .80+ man :)
Great call on Bfgc
I was being serious.
Anyone hearing anything on bldw? I think it may be time to sell and move on.
BFGC on alert @.38
Looking for $1+ on this deal!
Take a look at shell play CVRG float is incredibly small 1,247,931
I expect this to pop as the new company moves in permanently.
Converge Global, Inc. (CVRG) is a diverse company currently developing a division that will feature an online portal for the hospitality and food service industries to assist in identifying and securing products and services from the local, national and international marketplace.
What we do know:
This is currently a reactivated Shell stock as of Sept. 13, 2012
The float is an incredibly low 1,247,931 shares.
The New incoming company has not yet been named.
To bring CVRG back to life on OTCMarkets.com is very costly.
Fees:
$4,200 per year with a $500 setup fee.
http://www.otcmarkets.com/companies-advisors/disclosure-news/overview
Utah SOS was brought up to date Sept. 20, 2012
Sept. 30, 2012 financials that were posted on OTC Markets on Oct. 24th. 2012.
An Attorney letter was filed October 26th.
First Patients Recruited and Enrolled in Cellceutix Clinical Trial of Novel Anti-Cancer Drug Kevetrin
Print
Alert
Cellceutix Corp (OTCBB:CTIX)
Intraday Stock Chart
Today : Monday 29 October 2012
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to report that the first patients have been recruited and enrolled for the clinical trials of Kevetrin™, the Company's novel cancer drug in development. The clinical trials are being conducted on patients with advanced solid tumors at Harvard University's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center.
Based on dialogue with the clinical sites, the Company anticipates updating shareholders next week that dosing of the first patient has been administered.
"We are extremely pleased to hear that the first patients will begin therapy with Kevetrin™ in a matter of days," said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. "Not only is this is a substantial milestone for Cellceutix and its shareholders, but we feel it is important to the field of oncology. As a novel compound that directly impacts p53, the "Guardian Angel of the Human Genome," we look forward to a steady patient enrollment and future outcomes that potentially could change the landscape of cancer therapeutics.
Elsevier Business Intelligence
Cellceutix announced that Elsevier Business Intelligence has released a profile article on the Company for its latest edition of its publication "Start Up: Emerging Medical Ventures."
Elsevier, a division of Reed Elsevier Group PLC, is the world's leading provider of science and health information, serving more than 30 million scientists, students and health and information professionals worldwide.
In the article, Elsevier's Deborah Erickson discusses the uniqueness of the Company's Prurisol™ as a new therapeutic candidate for psoriasis, and the clinical trials at Dana-Farber Cancer Center and Beth Israel Deaconess on Kevetrin™ as a novel, p53-activating anti-cancer drug. Regularly referencing Cellceutix as "anything but a normal start-up," the write-up provides a succinct overview of the Company, its "all-star" advisory staff and offers insight into Kevetrin and Prurisol.
Shareholders and interested parties are encouraged to view the article at: http://cellceutix.com/category/in-the-news/
"We are very pleased to have been approached by Elsevier. They have a tremendous global outreach and the additional exposure is positive for our company," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "I found it particularly interesting how attracted they were to Prurisol and the incredible potential that they see for the drug. Because of the p53 connection and strong possibilities for Kevetrin™, many people overlook how impactful and valuable Prurisol can be as well."
About Kevetrin™
As a completely new class of chemistry in medicine, Kevetrin™ has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome") and that Kevetrin strongly induced apoptosis (cell death), characterized by activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.
In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time.
The clinical trial titled, "A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," is available at: http://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=1
About Prurisol
Prurisol is a small molecule, acting on the principles of immune modulation and PRINS reduction that has been found to be effective against psoriasis in animal models, both in induced psoriasis as well as a xenograft model with human psoriatic tissue. It is 25% orally bioavailable allowing the potential for oral administration. Prurisol was studied in SCID mice that were irradiated then engrafted with human psoriatic tissue by inserting human psoriatic tissue under the skin using a trocar. The results of the research showed that Prurisol significantly reduced all psoriatic endpoints measured relative to controls. More detailed information and images of the animal models can be found at: http://cellceutix.com/prurisol/
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
About Cellceutix
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". It is an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin™, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. More information is available on the Cellceutix web site at www.cellceutix.com.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix's success are more fully disclosed in Cellceutix's most recent public filings with the U.S. Securities and Exchange Commission.
Cellceutix Corp.
Leo Ehrlich
(978) 236-8717
Email Contact
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
117
|
Created
|
08/13/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |